User profiles for Mark R. Denison

Mark Denison or Denison MR or denison MR or denison MR

Vanderbilt University
Verified email at vanderbilt.edu
Cited by 29900

[HTML][HTML] SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

…, MC Nason, TJ Ruckwardt, JS McLellan, MR Denison… - Nature, 2020 - nature.com
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …

[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report

…, JD Chappell, MR Denison… - New England journal …, 2020 - Mass Medical Soc
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …

[HTML][HTML] Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

…, JY Feng, T Cihlar, R Jordan, MR Denison… - Nature …, 2020 - nature.com
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a
severe respiratory disease associated with more than 2468 human infections and over 851 …

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

…, ES Yang, Y Zhang, JD Chappell, MR Denison - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

…, AS Ray, T Cihlar, R Jordan, MR Denison… - Science translational …, 2017 - science.org
Emerging viral infections are difficult to control because heterogeneous members periodically
cycle in and out of humans and zoonotic hosts, complicating the development of specific …

[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

…, M Makhene, JD Chappell, MR Denison… - … England Journal of …, 2020 - Mass Medical Soc
Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …

[HTML][HTML] Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

…, M Makhene, JD Chappell, MR Denison… - … England Journal of …, 2021 - Mass Medical Soc
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

…, RL Mackman, MO Clarke, RS Baric, MR Denison - MBio, 2018 - Am Soc Microbiol
Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics
are available. The CoV nsp14 exoribonuclease (ExoN) has complicated development …

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

…, NJ Thornburg, R Swanstrom, MR Denison… - Science translational …, 2020 - science.org
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks,
most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of …

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

…, AN Kettenbach, MR Denison… - Proceedings of the …, 2017 - National Acad Sciences
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus
that since its emergence in 2012 has caused outbreaks in human populations with case-…